113 related articles for article (PubMed ID: 24563078)
21. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
[TBL] [Abstract][Full Text] [Related]
22. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.
Rodriguez M; Rose PG
Gynecol Oncol; 2001 Nov; 83(2):257-62. PubMed ID: 11606080
[TBL] [Abstract][Full Text] [Related]
23. The use of continuous infusion topotecan in persistent and recurrent ovarian cancer.
Elkas JC; Holschneider CH; Katz B; Li AJ; Louie R; McGonigle KF; Berek JS
Int J Gynecol Cancer; 2003; 13(2):138-41. PubMed ID: 12657113
[TBL] [Abstract][Full Text] [Related]
24. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
Herzog TJ; Powell MA; Rader JS; Gibb R; Mutch DG
Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766
[TBL] [Abstract][Full Text] [Related]
25. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
26. Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer.
Le T; Hopkins L; Baines KA; Rambout L; Fung-Kee-Fung M
Int J Gynecol Cancer; 2008; 18(3):428-31. PubMed ID: 17692088
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Weroha SJ; Oberg AL; Ziegler KL; Dakhilm SR; Rowland KM; Hartmann LC; Moore DF; Keeney GL; Peethambaram PP; Haluska P
Gynecol Oncol; 2011 Jul; 122(1):116-20. PubMed ID: 21514634
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
Ramasubbaiah R; Perkins SM; Schilder J; Whalen C; Johnson CS; Callahan M; Jones T; Sutton G; Matei D
Gynecol Oncol; 2011 Dec; 123(3):499-504. PubMed ID: 21955480
[TBL] [Abstract][Full Text] [Related]
30. A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer.
Vecchione F; Fruscio R; Dell'Anna T; Garbi A; Garcia Parra R; Corso S; Lissoni AA
Int J Gynecol Cancer; 2007; 17(2):367-72. PubMed ID: 17362314
[TBL] [Abstract][Full Text] [Related]
31. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer.
Tiersten A; Selleck M; Smith DH; Wertheim I; Kaufman E; Hershman D; Vahdat LT; Savage DG; MacArthur RB; Hesdorffer C
Int J Gynecol Cancer; 2006; 16(1):57-64. PubMed ID: 16445611
[TBL] [Abstract][Full Text] [Related]
33. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma.
Elkas JC; Winter WE; Chernofsky MR; Sunde J; Bidus MA; Bernstein S; Rose GS
Gynecol Oncol; 2007 Feb; 104(2):422-7. PubMed ID: 16996118
[TBL] [Abstract][Full Text] [Related]
34. Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study.
Bowman A; Rye T; Ross G; Wheatley A; Smyth JF
J Clin Oncol; 2001 Jul; 19(13):3255-9. PubMed ID: 11432893
[TBL] [Abstract][Full Text] [Related]
35. Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
Hoskins P; Eisenhauer E; Vergote I; Dubuc-Lissoir J; Fisher B; Grimshaw R; Oza A; Plante M; Stuart G; Vermorken J
J Clin Oncol; 2000 Dec; 18(24):4038-44. PubMed ID: 11118464
[TBL] [Abstract][Full Text] [Related]
36. Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.
Conteduca V; Gurioli G; Rossi L; Scarpi E; Lolli C; Schepisi G; Farolfi A; De Lisi D; Gallà V; Burgio SL; Menna C; Amadori A; Losi L; Amadori D; Costi MP; De Giorgi U
BMC Cancer; 2018 Dec; 18(1):1267. PubMed ID: 30567527
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer.
Verhaar-Langereis M; Karakus A; van Eijkeren M; Voest E; Witteveen E
Int J Gynecol Cancer; 2006; 16(1):65-70. PubMed ID: 16445612
[TBL] [Abstract][Full Text] [Related]
38. Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients.
Calcagno M; Bellati F; Palaia I; Plotti F; Basile S; Pastore M; Sansone M; Arrivi C; Angioli R; Panici PB
Int J Gynecol Cancer; 2009 Apr; 19(3):455-9. PubMed ID: 19407574
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
Gordon AN; Hancock KC; Matthews CM; Messing M; Stringer CA; Doherty MG; Teneriello M
Gynecol Oncol; 2002 Apr; 85(1):129-35. PubMed ID: 11925132
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
